Title: SARS-CoV-2 seroprevalence and gender-related haematological features in asymptomatic blood donors

Running Title: SARS-CoV-2 seroprevalence and gender-related haematological features

M Carmen Martín <sup>a</sup>, M Isabel González <sup>a</sup>, Nuria Holgado <sup>a</sup>, Ana I Jimenez <sup>a</sup>, Nuria Ortega <sup>a</sup>, Isabel Page <sup>a</sup>, Alba Parrado <sup>a</sup>, María Pérez <sup>a</sup>, Lydia Blanco-Peris <sup>a</sup>, <sup>a</sup> Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

**Corresponding author:** M Carmen Martín; <a href="mailto:cmartinalo@saludcastillayleon.es">cmartinalo@saludcastillayleon.es</a>; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

SARS-CoV-2 seroprevalence and gender-related hematological

features in asymptomatic blood donors

Abstract

Background and objectives: COVID-19 can either cause death or go

unnoticed but antibodies will remain protecting us of SARS-CoV-2

reinfection for an uncertain time and to an uncertain extent. Our aim was

to describe seroprevalence evolution from summer 2019 to autumn 2020

in Spain and to describe its relationship with age, blood group and

haematological parameters.

Materials and methods: Sera and plasma from historical donation

archives excluding convalescent were randomized and a total of 12,313

donations tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N

protein total immunoglobulins. Blood donors were 60.9% males, average

age 46+/-13. Sex, age, blood group, blood cell counts and percentages

and immunoglobulin concentrations were extracted from electronic

recordings.

Results: A seroprevalence of 6.7% in blood donors was found by the end

of the first wave. No differences by sex, age or blood group were found

regarding antibodies. Leukocyte count (p=0.026), haematocrit (p<0.001)

and haemoglobin (p<0.001) were lower in positive donations than in

negative ones. Sex differences were present in neutrophils, leukocytes,

haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.

Conclusions: Seroprevalence due to asymptomatic cases would

resemble that of global population. Sex and age would not affect COVID-

19 susceptibility but its severity. Gender differences related to COVID-19

in leukocytes, haemoglobin and haematocrit would be present in

asymptomatic individuals. Further studies are needed to confirm these

gender differences as they can help better understand the immune

response to COVID-19, its pathogenesis and prognosis.

**Keywords:** COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-

2

1

7

11

12

13

14

15

16

17

Introduction

2 An unknown amount of individuals infected with SARS-CoV-2 present no

3 symptoms or a mild disease that can go unnoticed. This make it difficult to

4 estimate infection rates, prevalence, calculating absolute risks of COVID-

5 19 or predicting the spread of the virus and the growth of herd immunity.

6 [1]. Immunization either due to infection or to vaccination leads specific T

cell responses and production of antibodies against SARS-CoV-2 usually

peaking 8-15 days after infection [2]. Antibodies that neutralize the virus 8

are the primary protection against COVID-19. 9

10 Antibody assays are quite different: they either detect antibodies against

different viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin

classes: IgG, IgM, IgA or their combinations. It should be noticed that

every approved vaccine in Europe to date (May 2020) enhances anti-S

responses, whereas an infection leads to a multi specific response to

SARS-CoV2 antigens. To make it even messier, many factors can

influence test performance, including cross-reactivity with

coronaviruses or platform (laboratory-based vs point-of-care, lateral flow).

19

20

21

22

23

24

25

26

27

28

29

31

32

33

34

35

36

37

38

39

41

Chemiluminiscence assays have suitable performances regarding both sensibility and sensitivity while correlation to neutralizing antibodies would be around 0.7 [3]. Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has accumulated nearly 225.000 COVID-19 confirmed cases (https://analisis.datosabiertos.jcyl.es/), with an overall case-fatality rate of 3.01 to date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its Biobank plasma samples from every single donation along the last ten years, that makes up around one million samples. Any demographic data such as sex or age and laboratory parameters (blood counts, blood group, haemoglobin, etc....) is as well kept in a database (Hemasoft, eDelphyn). 30 Blood donor-based serosurveillance is a powerful and cost-effective strategy to monitor infectious diseases. There are quite a lot of infections for which routine donor screening is undoubtedly useful, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or Crimea-Congo fever. The use of blood donor samples means we are sampling mainly asymptomatic and recovered cases of COVID-19 (donation is allowed after 28 days following COVID-19 resolution of symptoms). Seroprevalence surveys are then needed to monitor coronavirus 40 pandemic, both before and after vaccination strategies [4]. Reported COVID-19 cases do not represent the full SARS-CoV-2 disease burden

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

due to low detection rates, especially at the beginning of pandemics. Case reports are dependent on patients' seeking health care, massive local screenings or regional tracking activities. Analysis of data from seroprevalence and serosurveillance is a common strategy for estimating underreporting and real disease burden. Time between infection and antibody development or antibody waning must be considered to understand seroprevalence surveys avoiding biases. Serological surveys with a random sampling design of the general population are difficult to perform in a pandemic, but they would yield a seroprevalence estimate least likely to be affected by selection bias. Blood donors are a quite representative subset of general population aged 18-65 and our historical plasma collection was big enough to perform a systematic time-layered randomization. Heterogeneity of susceptibility and transmission are hard to evaluate [5]. A portion of the population is not susceptible to infection from the first pathogen contact. Some of them may have pre-existing immunity via cross-reactivity or particular host factors such as mucosal immunity or trained innate immunity protection (as it has been reported to be conferred by DTP or BCG vaccination)[6]. There is as well a proportion of seronegative individuals that will develop immunity by T cell mediated responses without exhibiting an antibody response [7]. Our starting hypothesis was the existence of a certain number of asymptomatic carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] and subsequently contribute to herd immunity.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Those asymptomatic cases were unnoticeable before SARS-CoV-2 testing began and might had been circulating from an unknown moment. Early cases have been described in France [8], arising the question of whether the pathogen could have been circulating before the official recording of the first cases. The main aim of this study was to determine which percentage of the population has had contact with SARS-CoV-2 at different times and had therefore developed antibodies against it. A secondary goal was to describe related haematological features of seropositive donors and establish whether sex, age, blood group or haematological abnormalities could be related to past COVID-19 infection. Knowledge of COVID-19 epidemiological and haematological features should help make a good forecast of resources for possible future outbreaks or vaccination strategies, and would facilitate decisions in the social sphere by a more reliable estimate of the percentage of immunized individuals. **MATERIAL and METHODS** Seroprevalence and haematological features were studied blood, plasma (excluding convalescent) and platelet donations from July 2019 to October 2020. The 101,183 donations from 70,181 donors collected since 19/07/2019 (week -24) to 19/10/2020 (week 43) were systematically randomized to select a minimum of 127 donations per week, calculated on the basis of the total number of donations and the length of the analysis period. Then, 1650 convalescent plasma donation were excluded. A total

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

of 12,718 samples of 12,313 donations from 11,444 donors over 18 years old were included. All haematological and demographic data were extracted from our electronic database eDelphyn (Hemasoft). Variables analysed included age, sex, blood group, and laboratory data: leukocyte (WBC), neutrophil, monocyte, eosinophil lymphocyte. platelet. and basophil (cells\*10<sup>3</sup>/µL) and their percentages, serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb), and haematocrit (HCT) were analysed as well. An automated chemiluminiscence double-antigen sandwich immunoassay for the in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human plasma and serum frozen samples. The target antigen of this immunoassay is a recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche, Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones and is therefore useful to help characterize the immune reaction to SARS-CoV-2 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic cases infected by mid-April, that were previously reported positive by the Spanish National Microbiology Centre, and checked to be as well positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2. Another set of ten prepandemic samples, therefore supposed to be negative, were equally analysed. 405 donations were analysed both in serum and plasma to verify interchangeability. A 100% concordance was

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

vielded by all these validation assays. The cut-off was that recommended by manufacturer (OD>1 to report reactivity). Researchers performing anti-SARS-CoV-2 analyses were blind to the condition of COVID-19 convalescence and to any other characteristic of the donors or to the donation dates. Demographic and clinical characteristics of patients are expressed as their mean, median, standard deviation (SD) and interquartile range (IQR) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-60 and 60-75 years old. Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. Only IgG and IgM serum levels followed normal distributions, therefore non-parametric Mann-Whitney U test was performed. To contrast independence of categorical variables, Pearson's Chi-square and Fisher's exact test were carried out. All tests were calculated with a confidence level of 0.05. The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011) with the number B.0000264. The institution holds an ISO 9001: 2015 certification endorsing our granting of safety and traceability of any human biological sample we distribute, always behaving Spanish and European rules on human samples and data protection management. This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. It was approved by the Valladolid Health Area Drug Research Ethics Committee, on June 11th, 2020 with the reference number BIO-2020-93. Included donors consented to participate in Biobank research activities. The privacy rights were always observed.

## Results

The 101,183 donations from 70,181 donors along 67 weeks (July 2019 to October 2020) were systematically randomized, discarding convalescent plasma ones and a total of 12,313 donations (either whole blood, plasmapheresis or platelet apheresis) were tested for total anti SARS-CoV-2 antibodies. Donors were 11,444 individuals, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3% O, 10.56% B, 3.31% AB. Baseline characteristics descriptive analyses are summarized in Table 1. Immunoglobulin results are usually performed only once a year in plasma donors.

Table 1. Baseline characteristics of donations

	n	mean	median	SD	IQR
Age	12313	44,0	45,8	12,8	34,2-54,3
lgG	199	1066,9	1038,0	217,8	910-1185
lgA	199	236,6	224,0	100,9	162-292
lgM	199	113,0	100,0	64,3	69-138
Leukocyte	10105	7,4	7,2	1,8	6,1-8,5
Haemoglobin	11604	14,9	14,9	1,3	14-15,8
Haematocrit	11604	45,1	45,1	3,5	42,6-47,5
Platelets	11603	247,9	243,0	54,3	211-280

Neutrophil count	11603	4,4	4,2	1,4	3,4-5,2
Neutrophil %	11603	58,8	58,9	7,5	53,8-63,9
Lymphocyte count	11602	2,3	2,3	0,7	1,9-2,7
Lymphocyte %	11602	31,7	31,5	6,9	27-36,2
Monocyte count	11602	0,5	0,5	0,1	0,4-0,6
Monocyte%	11602	6,5	6,4	1,5	5,5-7,4
Eosinophil count	11603	0,2	0,2	0,1	0,1-0,2
Eosinophil %	11603	2,5	2,1	1,8	1,3-3,2
Basophil count	11603	0,0	0,0	0,0	0-0
Basophil %	11603	0,5	0,5	0,2	0,3-0,6

No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of donations were found (Table 2).

Table 2. Sex, age range and blood group of positive/negative anti SARS-COV2 donations analysed

	Neg	ative	Positive		
	n	%	n	%	
Female	4531	38.1%	164	40.3%	
Male	7375	61.9%	243	59.7%	
<30	3551	29.8%	104	25.6%	
30 to 45	5036	42.3%	180	44.2%	
45 to 60	1151	9.7%	42	10.3%	
60 to 75	2168	18.2%	81	19.9%	

Α	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
В	919	7.7%	22	5.4%
0	5151	43.3%	171	42.0%

Three 2019 donations were reactive (from July, September and October; 1,142 donations from year 2019 were analyzed) but none of them were positive when testing separately IgG, IgA or IgM. Their ODs were 1.05, 1.08 and 5.46 respectively.

Seropositivity rate (positive donations x 100 / total analyzed donations per week) grew up from week 11 to week 25, reaching a 11.1% peak, with just subtle descents until week 43 when the second wave arose in our country. Plateau was reached by the last week of May 2020, 11 weeks after close lockdown in Spain and 17 weeks after 31/01, the date of the first declared case in or country. 660 out of 9,886 single donors were positive within weeks 11 to 43 (Fig 1). Seroprevalence was therefore 6.73% at the end of the

### 173 wave.

175

176

177




Fig 1. COVID-19 seropositive donation rate. 2020 evolution by weeks.

Immunoglobulin levels didn't show any differences as comparing positive and negative donations (Table 3). Haemoglobin (14.9 vs 14.7 g/dL; p<0.001) and haematocrit (45.2% vs 44.4%; p<0.001) were both significantly lower in positive donations. Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells\*10 $^3$ /µL; p=0.026). Trends were found of lower number of neutrophils (4.3 vs. 4.2 cells\*10 $^3$ /µL; p=0.117), lower count of monocytes (0.46 vs. 0.45 cells\*10 $^3$ /µL; p=0.117) and higher percent of basophils (0.49% vs 0.51%; p=0.131) in positive donations as compared with negative ones.

Table 3. Descriptive analyses of age, immunoglobulins and haemogram of

# reactive and non-reactive donations

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	45.8	12.8	34.2-54.2
	Positive	407	44.2	46.5	13.0	32.8-54.8
IgA	Negative	194	236.9	223.5	101.3	163-292
	Positive	5	224.4	274.0	92.3	134-282
IgG	Negative	194	1065.4	1037.5	217.4	910-1185
	Positive	5	1123.8	1095.0	249.9	924-1229
IgM	Negative	194	113.3	100.5	64.8	69-138
	Positive	5	103.0	89.0	41.7	78-97
WBC <sup>a</sup>	Negative	9759	7.4	7.2	1.8	6.13-8.49
	Positive	346	7.2	7.1	1.6	6.11-8.12
Hb <sup>b</sup>	Negative	11218	14.9	14.9	1.3	14-15.8
	Positive	386	14.7	14.7	1.2	13.8-15.4
Hematocrite <sup>b</sup>	Negative	11218	45.1	45.2	3.5	42.7-47.6
	Positive	386	44.5	44.4	3.5	42.3-46.6
Platelets	Negative	11217	247.9	243.0	54.3	211-280
	Positive	386	247.3	242.5	55.7	206-276
Neutrophil						
count c	Negative	11217	4.4	4.3	1.4	3.44-5.19
	Positive	386	4.3	4.2	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	58.9	7.5	53.8-63.9
	Positive	386	58.5	58.7	7.1	54.3-63.4

Lymphocyte						
count	Negative	11216	2.3	2.3	0.7	1.86-2.72
	Positive	386	2.3	2.2	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	31.5	6.9	27-36.2
	Positive	386	32.1	32.4	6.6	27.3-36.1
Monocyte						
count d	Negative	11216	0.5	0.46	0.1	0.38-0.56
	Positive	386	0.5	0.46	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	6.4	1.5	5.5-7.4
	Positive	386	6.5	6.4	1.4	5.5-7.3
Eosinophil						
count	Negative	11217	0.2	0.2	0.1	0.09-0.23
	Positive	386	0.2	0.1	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	2.1	1.8	1.3-3.2
	Positive	386	2.4	2.0	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	0.0	0.0	0.02-0.04
	Positive	386	0.0	0.0	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	0.5	0.2	0.3-0.6
	Positive	386	0.5	0.5	0.3	0.4-0.6

Units: Immunoglobulins (mg/dL); Hb (g/dL); haemogram counts

180 a p=0.026

<sup>b</sup> p<0.001

182 ° p=0.117

<sup>179 (</sup>cells\* $10^3/\mu$ L)

<sup>d</sup>p=0.131

As layering data by sex (Table 4), the fact arose that haematocrit (46.8% vs 45.9%; p<0.001) and haemoglobin (15.5 vs 15.3 g/dL; p<0.001) were significantly lower just in males and that positive females had significantly less WBC (7.67 vs 7.25 cells\* $10^3$ /µL; p=0.027) and neutrophil numbers (4.53 vs 4.27 cells\* $10^3$ /µL; p=0.014).

Table 4. Descriptive analysis of age, age, immunoglobulins and haemogram of reactive and non-reactive donations layered by sex

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	43.50	13.3	30.3-53.3
		Positive	164	42.1	45.39	13.6	28.6-53.1
	Male	Negative	7375	45.2	46.81	12.2	36.7-54.8
		Positive	243	45.7	46.98	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	200.00	97.0	157-250
		Positive	3	235.3	274.00	105.5	116-316
	Male	Negative	140	245.6	233.50	101.9	176.5-302.5
		Positive	2	208.0	208.00	104.7	134-282
IgG	Female	Negative	54	1076.4	1062.50	191.3	964-1186
		Positive	3	1082.7	1095.00	152.9	924-1229
	Male	Negative	140	1061.2	1029.00	227.2	903-1181.5
		Positive	2	1185.5	1185.50	436.3	877-1494
IgM	Female	Negative	54	143.1	129.50	64.6	94-169
		Positive	3	114.3	89.00	53.7	78-176
	Male	Negative	140	101.8	90.00	61.3	64.5-121

		Positive	2	86.0	86.00	15.6	75-97
Mean							
corpuscular							
volume	Female	Negative	3618	91.2	91.50	4.8	88.4-94.4
		Positive	142	91.2	91.40	4.1	88.9-93.5
	Male	Negative	6141	90.9	91.00	4.6	88.1-93.8
		Positive	204	90.6	91.00	4.8	88-94.1
WBC	Female	Negative	3618	7.8	7.69	1.9	6.49-9
		Positive	142	7.4	7.21	1.5	6.27-8.26
	Male	Negative	6949	7.2	7.02	1.8	5.99-8.2
		Positive	229	7.1	6.98	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	13.80	0.9	13.2-14.4
		Positive	157	13.7	13.80	0.9	13.2-14.3
	Male <sup>b</sup>	Negative	6949	15.5	15.50	1.0	14.9-16.2
		Positive	229	15.3	15.30	1.0	14.7-15.8
Haematocrit	Female	Negative	4269	42.4	42.30	2.7	40.6-44
		Positive	157	42.1	42.00	2.5	40.5-43.6
	Male <sup>b</sup>	Negative	6949	46.8	46.80	2.8	45-48.6
		Positive	229	46.2	45.90	3.0	44.3-47.7
Platelets	Female <sup>c</sup>	Negative	4268	265.9	261.00	56.6	228-300
		Positive	157	261.0	255.00	60.5	219-296
	Male	Negative	6949	236.8	233.00	49.6	204-266
		Positive	229	237.9	234.00	50.2	203-266
Neutrophil							
count	Female	Negative	4268	4.7	4.53	1.4	3.65-5.47

		Positive	157	4.4	4.27	1.2	3.56-5.08
	Male	Negative	6949	4.3	4.10	1.4	3.34-4.95
		Positive	229	4.2	4.10	1.2	3.24-4.97
Neutrophil							
%	Female	Negative	4268	59.2	59.40	7.4	54.2-64.3
		Positive	157	58.1	58.10	7.2	54-62.9
	Male	Negative	6949	58.6	58.70	7.5	53.6-63.6
		Positive	229	58.8	58.70	7.0	54.6-63.5
Lymphocyte							
count	Female	Negative	4267	2.5	2.39	0.7	1.97-2.88
		Positive	157	2.4	2.35	0.6	2.02-2.81
	Male	Negative	6949	2.2	2.18	0.6	1.8-2.62
		Positive	229	2.2	2.17	0.6	1.8-2.51
Lymphocyte							
%	Female <sup>e</sup>	Negative	4267	32.0	31.70	6.9	27.4-36.5
		Positive	157	33.0	33.10	7.0	28.4-37
	Male	Negative	6949	31.5	31.30	6.9	26.8-36.1
		Positive	229	31.4	31.70	6.3	26.7-35.6
Monocyte							
count	Femalef	Negative	4267	0.5	0.46	0.1	0.37-0.55
		Positive	157	0.5	0.44	0.1	0.36-0.52
	Male	Negative	6949	0.5	0.46	0.1	0.38-0.56
		Positive	229	0.5	0.47	0.1	0.38-0.55
Monocyte							
%	Female	Negative	4267	6.1	6.00	1.4	5.1-6.9

		Positive	157	6.1	6.00	1.4	5.2-6.9
	Male	Negative	6949	6.7	6.60	1.5	5.7-7.6
		Positive	229	6.7	6.70	1.4	5.8-7.6
Eosinophil							
count	Female	Negative	4268	0.2	0.14	0.1	0.09-0.21
		Positive	157	0.2	0.13	0.1	0.09-0.19
	Male	Negative	6949	0.2	0.16	0.1	0.1-0.24
		Positive	229	0.2	0.15	0.1	0.09-0.23
Eosinophil							
%	Female	Negative	4268	2.2	1.80	1.6	1.2-2.8
		Positive	157	2.3	1.80	1.7	1.1-2.8
	Male	Negative	6949	2.7	2.20	1.8	1.4-3.4
		Positive	229	2.5	2.10	1.7	1.4-3.2
Basophil							
count	Female	Negative	4268	0.0	0.03	0.0	0.02-0.05
		Positive	157	0.0	0.04	0.0	0.02-0.05
	Male	Negative	6949	0.0	0.03	0.0	0.02-0.04
		Positive	229	0.0	0.03	0.0	0.02-0.04
Basophil %	Female <sup>g</sup>	Negative	4268	0.5	0.40	0.2	0.3-0.6
		Positive	157	0.5	0.50	0.3	0.3-0.6
	Male	Negative	6949	0.5	0.50	0.2	0.3-0.6
		Positive	229	0.5	0.50	0.2	0.4-0.6

<sup>191 \*</sup>p<0.05

Units:immunoglobulins (mg/dL); Hb(g/dL); haemogram counts

<sup>193 (</sup>cells\*10<sup>3</sup>/μL) and percent

194	<sup>a</sup> p=0.027
195	<sup>b</sup> p<0.001
196	<sup>c</sup> p=0.152
197	<sup>d</sup> p=0.065
198	<sup>e</sup> p=0.074
199	<sup>f</sup> p=0.132
200	<sup>9</sup> p=0.060
201	
202	
203	Some trends were found as well related to sex. Regarding positive women
204	neutrophil percent would be lower (59.4% vs 58.10% p=0.065),
205	lymphocyte percent, higher (31.7% vs 33.10%; p=0.074), platelet count,
206	(261 vs 255 cells* $10^3/\mu L$ ; p=0.152), monocyte count (0.46 vs 0.44
207	cells* $10^3/\mu$ L; p=0.132) and basophil percent (0.5% vs 0.4%; p=0.060)
208	lower. Anaemia was more frequent in positive male donors as (6.1% vs
209	9.6%; p=0.031). No other significant differences were found either in
210	males, females or overall (Fig 2).

	Overall	Male	Female
Hb	Ψ	Ψ	-
Hematocrite	Ψ	Ψ	1-3
Leukocyte count	Ψ	3_4	Ψ
Platelet count	-	10.700	Ψ
Neutrophil count	4		Ψ
Neutrophil %	-	-	1
Lymphocyte count	-	3_4	Ψ
Lymphocyte %	-	N.700	Ψ
Monocyte count	4	-	Ψ
Basophil %	1	-	Ψ

Fig 2. Summary of haematological features in SARS-CoV-2 positive donations as compared to negative ones. Intense-coloured arrows represent significant differences. Light-coloured arrows represent statistical trends.

## **Discussion**

A similar seroprevalence to that reported in general population was found among blood donors without COVID-19 antecedents. The 6.73% seroprevalence is a little lower than that reported in the seroprevalence study ENE-COVID-19 promoted by the *Instituto Nacional the Epidemiología* [11], where it is reported that a 7.2% of the participants in our region would have anti SARS-CoV2 IgG antibodies by the end of June 2020. Almost one quarter people in our region (25.51% according to National Institute of Statistics, INE 2020 data) is older than 65 and elderly are necessarily underrepresented in this study. That happens as well with

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

population aged under 18 (<4.5% in our region). One limitation of this study is this of restricted age, but it would make just a little difference of 0.5% in seroprevalence estimation. Immunization rate would be a bit higher regarding the fact that some individuals who do not exhibit antibodies but still mount an efficient specific T-cell response [2] Perhaps the main strength of our study is the large number of samples we randomized and the long period we tested (15 months). The first recorded COVID-19 case in Spain was reported on 31/01/2020, but three positive donations were found as testing samples collected along 2019. That could be meaningful in two opposite ways: one possible explanation would be cross reactivity to seasonal cold coronaviruses and the other would be that SARS-CoV-2 might have been circulating at least since 2019 summer. It is now known that up to 28% people would have protection against SARS-CoV-2 due to cross reaction to other coronaviruses [2]. It has been checked that long-term cross-reactive both T-cells and antibodies can be correlates of protection against COVID-19 [12]. Asymptomatic or mild cases couldn't be diagnosed or reported before the first tests were available. There are other reports about SARS-CoV-2 circulating in Europe along 2019 [13]. Our three 2019 positive donors would be even earlier cases, but the simplest explanation would be that of crossreactions. Some of the positives along the period of study might be as well cross-reactive or both reactive due to SARS-CoV-2 infection together with previous coronavirus immunity.

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an influence on the probability to develop an asymptomatic COVID-19 infection in our cohort. Several smaller seroprevalence reports from European countries support this feature [16-20]. Age and sex would not therefore have a role in SARSCoV-2 infection susceptibility, but only in their progression to severe forms. Blood group has been reported elsewhere [7,21-23] to confere susceptibility or determine severity of SARS-CoV2 infection. Most published studies do not separate them. It should be noticed that there are no large studies characterizing asymptomatic cases in literature, perhaps this is one of the reports comprising one of the largest asymptomatic cohorts to date. Relationship of ABO system with susceptibility is not supported by our data. We excluded convalescent plasma donors, opposite to other published studies, that focused into these asymptomatic positive donors [22]. Perhaps blood group might play a role only in symptomatic cases and would be therefore related to severity but not to asymptomatic SARS-CoV-2 infection. Another surface antigens such as HLA or KIR might be as well involved and should be studied. Several blood count anomalies have been reported in SARS-CoV2 infection, notably lymphopenia and neutrophilia are related to the severest forms [24]. Our data conversely reveal that asymptomatic positive women had a significant lower count of WBC and neutrophils as compared to negative ones. Similar low counts of WBC and neutrophils have been reported in young (<19) cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this feature might be therefore a correlate of mildness. Elevations of monocytes have been elsewhere reported in short series of mild cases [26]. Our observation will be in the same line of those findings but a gender bias cannot be discarded so far seropositive women would go in the opposite direction. Several reports about haemolytic anaemia secondary to SARSCoV-2 have been published [27-30]. We cannot discard a mild silent haemolytic anaemia in asymptomatic cases but just small asymptomatic cohorts are published to date. We can conclude that seroprevalence estimations through blood donation analysis mirror population-based surveys. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences are present even in asymptomatic individuals: positive females have lower lymphocyte counts whereas positive males, present anaemia more frequently than negative ones. Further studies in large cohorts are needed to confirm these gender differences and to characterize asymptomatic COVID-19 cases as they can help better understand immune response to COVID-19, its pathogenesis and prognosis.

# Acknowledgements

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data, IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and LB drafted the article and revised it critically for

important intellectual content, all authors provided final approval of the version to be submitted.

The authors thank to all blood donors for making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and Roche for its support.

#### References

- 1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. Clin Infect Dis. 2020;72(2):254-256.
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID: PMC7427556.
- 3. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, et al. Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. Vox Sang. 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23. PMID: 33368373.
- 4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open.* 2021;4(1):e2033706.
- 5. Friston K, Costello A, Pillay D. 'Dark matter', second waves and epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978.
- 6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. *J Clin Invest*. 2021;131(2):e145545.
- 7. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2021;27(1):113–21
- 8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res.* 2020;181:104880
- 9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol*. 2020;129:104480
- Müller L, Ostermann PN, Walker A, Wienemann T, Mertens A, Adams O, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. Eur J Clin Microbiol Infect Dis. 2021 May;40(5):1063-1071. doi: 10.1007/s10096-021-04169-7. Epub 2021 Feb 3. PMID: 33534090; PMCID: PMC7856849.
- 11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ.

- 2020 Nov 27;371:m4509. doi: 10.1136/bmj.m4509. PMID: 33246972; PMCID: PMC7690290.
- 12. Poonia B, Kottilil S. Immune Correlates of COVID-19 Control. *Front Immunol.* 2020;11:569611
- 13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in emergency departments as a COVID-19 surveillance system: a time series study. BMJ Open. 2021;11(2):e044388.
- 14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17:22
- 15. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w. PMID: 34016150; PMCID: PMC8134808.
- Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, et al. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Public Health. 2021 Jan;190:132-134. doi: 10.1016/j.puhe.2020.11.014. Epub 2020 Nov 24. PMID: 33453689; PMCID: PMC7685039.
- 17. Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. doi: 10.1016/S2214-109X(20)30387-9. Epub 2020 Sep 23. PMID: 32979314; PMCID: PMC7511212..
- 18. Bogogiannidou Z, Speletas M, Vontas A, Nikoulis DJ, Dadouli K, Kyritsi MA, et al. Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020. Vaccines (Basel). 2021 May 13;9(5):504. doi: 10.3390/vaccines9050504. PMID: 34068100; PMCID: PMC8152765.
- 19. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396(10247):313-319
- 20. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses*. 2021;13(2):160
- 21. Muñiz-Diaz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus. 2021 Jan;19(1):54-63. doi: 10.2450/2020.0256-20. Epub 2020 Nov 12. PMID: 33196417; PMCID: PMC7850930.

- 22. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. Infección y trombosis asociada a la COVID-19: posible papel del grupo sanguíneo ABO. Med Clin (Barc). 2020;155(8):340-343. doi:10.1016/j.medcli.2020.06.020
- 23. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. *Eur J Haematol.* 2020;105(5):540-546
- 24. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19 under 19: A meta-analysis. Pediatr Pulmonol. 2021 Jun;56(6):1332-1341. doi: 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606
- 25. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection. Cytometry A. 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020 Aug 14. PMID: 32654350; PMCID: PMC7404377
- 26. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M, et al. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report. Ther Adv Hematol. 2021 Apr 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID: 33995989; PMCID: PMC8082984.
- 27. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic Anemia Associated With Asymptomatic SARS-CoV-2 Infection. Cureus. 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918; PMCID: PMC8075761.
- 28. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ, et al. Evans syndrome and immune thrombocytopenia in two patients with COVID-19. J Med Virol. 2021 May;93(5):2642-2644. doi: 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID: PMC8013600.
- 29. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N, Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. Leuk Lymphoma. 2021 Feb 22:1-5. doi: 10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.
- 30. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. Int J Biol Sci. 2021 Jan 1;17(1):62-72
- 31. Dattilo M. The role of host defences in Covid 19 and treatments thereof. *Mol Med.* 2020;26(1):90

294

Abbreviations

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polymerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT)